Information Provided By:
Fly News Breaks for December 16, 2019
HZNP
Dec 16, 2019 | 04:53 EDT
Stifel analyst Annabel Samimy raised her price target for Horizon Pharma to $40 from $35 citing an FDA panel's unanimous vote recommending approval of teprotumumab. Overall, teprotumumab approval seems unquestionable, with discussions leading to a conclusion of allowing maximum access to finally give thyroid eye disease patients a real option, Samimy tells investors in a research note. She keeps a Buy rating on Horizon Pharma shares.
News For HZNP From the Last 2 Days
There are no results for your query HZNP